Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant

Clin Lymphoma Myeloma Leuk. 2013 Sep:13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017.
No abstract available

Keywords: Complete molecular remission; Minimal residual disease; Molecular relapse; Ph+ acute lymphoblastic leukemia; Tyrosine kinase inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Combined Modality Therapy
  • Dasatinib
  • Female
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Stem Cell Transplantation / methods*
  • Thiazoles / therapeutic use*
  • Transplantation, Homologous
  • Young Adult

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Dasatinib